Corticosteroids diffuse across cell membranes and complex with specific cytoplasmic receptors . These complexes then enter the cell nucleus , bind to DNA (chromatin) and stimulate transcription of mRNA and subsequent protein synthesis of various inhibitory enzymes responsible for the anti – inflammatory effects of topical corticosteroids . These anti – inflammatory effects include inhibition of early processes such as edema , fibrin deposition , capillary dilatation , movement of phagocytes into the area , and phagocytic activities. Later processes , such as capillary production , collagen deposition , and keloid formation also are inhibited by corticosteroids . The overal actions of topical corticosteroids are catabolic.

Topical Betamethasone is indicated to provide symptomatic relief of inflammation and/or pruritus associated with acute and chronic corticosteroid – responsive disorders including: atopic dermatitis, contact dermatitis , nummular dermatitis , seborrheic dermatitis ( facial and intertriginous) , intertrigo , lichen planus , discoid lupus erythematosus , sunburn , anogenital pruritus , psoriasis , inflammatory phase of xerosis , alopecia areata , granuloma annulare , pemphigoid , pemphigus , pityriasis rosea , and sarcoidosis.

Allergic contact dermatitis ; Folliculitis ; Furunculosis ; Pustules ; Pyoderma or vesiculation ; Hyperesthesia ; Numbness in fingers ; Purpura ; Skin atrophy ; Secondary skin infection ; Telangiectasia ; Mild and transient burning , dryness , irritation , itching , or redness of skin ; Mild and transient increased redness or scaling of skin lesions ; Minor and transient skin rash ; Mild and temporary stinging . Percutaneous absorption of topical corticosteroids has resulted in systemic side effects including acneiform eruptions , Cushing’s syndrome , perioral dermatitis , ecchymosis , edema , gastric ulcer , hirsutism or hypertrichosis , hypertension , hypokalemic syndrome , hypopigmentation or other changes in skin pigmentation , aggravation of infection , miliaria rubra , protein depletion , skin laceration , skin maceration , striae , subcutaneous tissue atrophy , unusual loss of hair (especially on the scalp).

hypersensitivity to betamethasone or any component of the formulation

Risk – benefit should be considered when the following medical problems exist : Infection at treatment site and pre – existing skin atrophy . Do not use occlusive dressings on weeping or exudative lesions and general caution with occlusive dressings should be observed . Discontinue if skin irritation or contact dermatitis should occur . Do not use in patients with decreased skin circulation.

Periodic monitoring of adrenal function assessment , including blood or urine cortisol concentration or ACTH stimulation test , may be advisable during and following use if factors that increase percutaneous absorption are present and treatment is prolonged.